Global Medical Lasers Market

Joint Reconstruction Devices And Equipment Market Definition

The joint reconstruction devices and equipment market consists of sales of joint reconstruction devices and equipment and related services. Joint reconstruction devices and equipment are used in joint reconstruction procedures such as shoulder replacement, ankle replacement, digit replacement, hip replacement, elbow replacement, knee replacement, and elbow replacement. The joint reconstruction devices and equipment market covers implantable medical devices that are intended to operate (either alone or together with one or more other implantable medical devices) as a replacement (in whole or in part) for the, elbow joint, ankle joint, digit joints, shoulder joint, hip joint and knee joint. The market also covers equipment used for joint reconstruction which includes orthopedic surgery navigation systems, surgical power tools, shaver blades, meniscal rasps, cast saws, pulsed lavage systems, bone punches, arthroscopes, orthopedic screwdrivers, orthopedic burrs, graft preparation systems, tissue matrices, and bone substitutes.

Dialysis Devices and Equipment Market Definition

The dialysis devices and equipment market consists of the sale of dialysis devices and equipment and related services by entities (organizations, sole traders and partnerships) that manufacture dialysis devices and equipment which are used in the treatment of dialysis patients. The dialysis devices and equipment industry includes establishments that manufacture dialysis devices and equipment such as dialyzers and dialysis pumping machines and other instruments used in the dialysis process, including blood pumps, catheters and tubing kits. Dialysis devices and equipment are used in the dialysis process to filter the patient’s blood, in order to remove waste products such as urea, creatinine and excess water, such impurities usually occur when the kidneys fail or are damaged. Dialysis allows patients with kidney failure a chance to live productive lives. There are three types of dialysis – hemodialysis dialysis, peritoneal dialysis and continuous renal replacement.

Pulse Oximeters And Spirometers Market Definition

The pulse oximeters and spirometers market consists of sales of pulse oximeters and spirometers that are used as respiratory care devices, and to check on general health, in the healthcare industry. The market includes the sales of handheld, tabletop or fingertip pulse oximeters that are used to monitor the oxygen saturation levels of the blood and pulse rate, as well as handheld, desktop or tabletop spirometers that are used to measure the air capacity of lungs. Pulse oximeters and spirometers companies are primarily engaged in the manufacturing and developing of these devices used to monitor the respiration-related parameters that aid in the detection of respiratory disorders.

Wearable Blood Pressure Monitor Market Definition

The wearable blood pressure monitor market consists of the sale of wearable blood pressure monitors and related services. The market comprises of revenue generated by business enterprises that manufacture, develop and sell wearable blood pressure monitors. Wearable blood pressure monitors are devices that continuously monitor blood pressure even during activities such as exercise and sleep using technology that is connected to the wearer`s body. The data is stored and analyzed through an app. A wearable blood pressure monitor is a wearable pocket-sized blood pressure monitor that has a small real-time graphical display and provides reports and/or synchronizes data with smart phones and PCs. They are usually battery operated and store data.

Sterilization Equipment And Disinfectants Market Definition

The sterilization equipment and disinfectants market consists of sales of sterilization equipment and disinfectants by entities (organizations, sole traders and partnerships) that produce sterilization equipment and disinfectants, which are used in the decontamination of microorganisms from equipment and supplies. The manufactures of sterilization equipment and disinfectants are primarily engaged in manufacturing equipment which is used for decontamination by physical, chemical and mechanical methods by hospital and clinics, clinical laboratories, pharmaceutical companies, food and beverage industry and households.

The breast imaging devices market consists of sales of breast imaging devices and related services by entities (organizations, sole traders, and partnerships) that manufacture breast imaging devices. Breast imaging devices are medical devices used in the diagnosis of medical conditions related to the breast. The main product types in breast imaging devices are tomosynthesis, breast ultrasound, breast MRI, mammography, nuclear imaging, and others. Tomosynthesis is an imaging method that is utilized to screen early signs of breast cancer in people with no symptoms. This kind of imaging can also be utilized as a diagnostic tool for a person who is having breast cancer symptoms. The technologies involved in breast imaging devices are ionizing and non-ionizing. These are used in hospitals and clinics, breast care centers, and diagnostic imaging centers. The global breast imaging devices market size is expected to grow from $4.06 billion in 2021 to $4.31 billion in 2022 at a compound annual growth rate (CAGR) of 6.3%. The global breast imaging market size is then expected to grow to $5.27 billion in 2026 at a CAGR of 5.2%. The rising prevalence of breast cancer is anticipated to contribute to the breast imaging devices market’s growth. A growing number of hormone replacement therapy (HRT), hormonal imbalances, menopause, and various reproductive disorders have significantly increased the risks of breast cancer. According to the World Health Organization (WHO), breast cancer is the most common cancer in women, impacting 2.1 million women annually. Breast cancer causes the highest number of cancer-related deaths among women. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The high cost associated with breast imaging devices is expected to limit the growth of the market shortly. The cost of digital mammography systems varies for different models and companies. For instance, the cost of the 2D model’s mammography systems ranges between $65,000 to $95,000 for GE Healthcare and Hologic, Inc products. Whereas 3D models of the same company range between $90,000 to $200,000. In addition to this, the premium 3D models of GE Healthcare and Hologic Inc. are priced between $1,40,000 to $2,75,000. Therefore, the high cost of breast imaging systems is a major concern for end-users, which is predicted to hinder the growth of the breast imaging devices market over the forecast period. Major players operating in the breast imaging devices market are undertaking various strategic initiatives such as the launch of technologically advanced or innovative products and product portfolio expansion, which is likely to be a leading trend in the breast imaging market. Various companies are introducing new advanced devices in the market to attract a large customer base and maintain their position in the competitive business environment. For instance, in March 2021, Siemens Healthineers, a company operating in breast imaging devices based in Germany launched a new software solution Mammovista B.smart that works on AI technology and boosts the breast image reading process, tracks, and analyses the workflow. It has features such as it reduces the loading time and helping the radiologist in reading the number of patient databases. In June 2019, Hologic, Inc., a USA-based innovative medical technology company focused on improving women's health and well-being through early treatment and diagnosis, announced the acquisition of SuperSonic Imagine for an amount of $85 million. With the acquisition of SuperSonic Imagine, Hologic, Inc. aims to gain entry into cart-based breast ultrasound technology used to screen women with dense breast tissue. SuperSonic Imagine is a France-based company specialized in ultrasound medical imaging including breast imaging devices. Major players in the breast imaging devices market are Siemens Healthcare, GE Healthcare, Dilon Technologies Inc, Hologic Inc, Gamma Medica Inc, Fujifilm Holdings Corporation, SonoCine Inc, Philips Healthcare, Toshiba Corporation, and Aurora Imaging Technology Inc. North America was the largest region in the breast imaging devices market in 2021. Asia Pacific was the second largest market in the global breast imaging device market. The regions covered in the global breast imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the breast imaging devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global breast imaging devices market is segmented - 1) By Product Type: Tomosynthesis, Breast Ultrasound, Breast MRI, Mammography, Nuclear Imaging, Others 2) By Technology: Ionizing, Non Ionizing 3) By End-User: Hospitals and Clinics, Breast Care Centers, Diagnostic Imaging Centers

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders, and partnerships) that produce breast cancer diagnostics devices. These devices are used to diagnose breast cancer. Only goods and services traded between entities or sold to end consumers are included. The main types of breast cancer diagnostics are Imaging, biopsy, genomic tests, blood tests, and others. The biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technology involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are brca breast cancer, er & pr breast cancer, her 2-breast cancer, egfr mutation test breast cancer, and others. The diagnostic types involved are ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers. The global breast cancer diagnostics market size is expected to grow from $3.75 billion in 2021 to $4.06 billion in 2022 at a compound annual growth rate (CAGR) of 8.3%. The global breast cancer diagnostic market is then expected to grow to $5.48 billion in 2026 at a CAGR of 7.8%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer and 685,000 people died of breast cancer in 2020. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to a 2019 study conducted by Mesothelioma Center, around 63% of respondents that comprise of people with cancer and their family members reported financial difficulties. For instance, the total cost of diagnosis for breast cancer was $353 per patient but diagnostic costs varied from $151 in some regions to $751 in others. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In March 2019, Southwest Medical Center, a US-based company, launched 3D mammography services that provide patients with access to enhanced breast imaging services closer to home. In November 2019, EXACT Sciences Corporation, a US-based molecular diagnostics company, acquired Genomic Health for $2.8 billion. Through this acquisition, Exact Sciences will be able to facilitate therapy decisions for colorectal, breast, and prostate cancers by Genomic Health’s Oncotype DX gene expression. Genomic Health is a US-based genomic diagnostics manufacturer. Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc, Hologic Inc, Koninklijke Philips N.V, Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc, Siemens AG, NanoString Technologies Inc, and C. R. Bard Inc. North America was the largest region in the breast cancer diagnostics market in 2021. Asia Pacific was the second largest region in the global breast cancer diagnostics market. The regions covered in the global breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Others 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Others 3) By Cancer Type: BRCA Breast Cancer, ER and PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Others 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-Ionizing Imaging Technologies 5) By End-User: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders, and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer. The main types of cervical cancer diagnostics are pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic tests. The pap smear test is the process of testing cervical cancer in women. The age group involved are below 21, age between 21 to 29, age between 30 to 65, and above 65. The end-users involved are hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. The global cervical cancer diagnostics market size is expected to grow from $7.78 billion in 2021 to $8.29 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%. The global cervical cancer diagnostic market is expected to grow to $10.54 billion in 2026 at a CAGR of 6.2%. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2019, the United States Preventive Services Task Force has updated its screening guidelines for cervical cancer, which specifies that women between ages 21 to 29 should be screened with a Pap test every 3 years, women between ages 30 to 65 should be screened with any of three tests, namely high-risk HPV testing alone, Pap and high-risk HPV contesting for every 5 years and Pap test alone for every 3 years. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. For instance, in January 2019, Nurx, a consumer health and telemedicine company, introduced lab testing that allows women to easily and affordably monitor their risk of cervical cancer from the comfort of their homes. Similarly, in April 2019, Matter introduced three conceptual cervical cancer examinations through the Sukha project that help women carry out tests at home to break the stigma associated with cervical testing. In May 2020, The USA-based firm, Becton, Dickinson & Co, a manufacturer and seller of medical devices, instrument systems, and reagents announced the acquisition of San Diego biomedical business CareFusion for $12.2 billion. The acquisition is expected to improve the quality of patient care and reduce health care costs by identifying the needs in hospitals, hospital pharmacies, and alternate sites of care. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Hologic Inc, QIAGEN NV, Quest Diagnostics Inc, Siemens Healthineers AG, Zilico, and Guided Therapeutics. North America was the largest region in the cervical cancer diagnostics market in 2021. Asia Pacific was the second largest region in the global cervical cancer diagnostics market. The regions covered in the global cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cervical cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global cervical cancer diagnostics market is segmented - 1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Others 2) By End-User: Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres 3) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65